Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Vikas Dudeja

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9224-777X; OpenAlex author ID A5076908226. Sources: OpenAlex.

Their work

Papers
48 (first author 5, last author 9)
Trials
0
Grants
0
Labs led
3
Collaborators
75
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 3 papers · 2014: 3 papers · 2015: 2 papers · 2016: 5 papers · 2017: 3 papers · 2018: 3 papers · 2019: 7 papers · 2020: 2 papers · 2021: 6 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers

Papers 48

  1. Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancrea… Last author DOI 10.1007/s00535-025-02213-3↗
  2. Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-Analysis. Co-author DOI 10.1016/j.jss.2025.04.042↗
  3. Corrigendum to 'Neoadjuvant Therapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: A Systemic Review and Meta-analysis' Jou… Co-author DOI 10.1016/j.jss.2025.10.015↗
  4. An Analysis on the Effect of Income Changes in the Resection of Early-Stage Pancreatic Adenocarcinoma. Co-author DOI 10.1177/00031348241256058↗
  5. Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer? Co-author DOI 10.1016/j.jss.2022.11.031↗
  6. Peritoneal Cell-Free DNA: A Novel Biomarker for Recurrence in Pancreatic Cancer. Last author DOI 10.1245/s10434-023-13947-w↗
  7. Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.amjsurg.2022.04.004↗
  8. Minnelide synergizes with conventional chemotherapy by targeting both cancer and associated stroma components in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215591↗
  9. Prescription patterns of pancreatic enzyme replacement therapy for patients with pancreatic cancer in the United States. Last author DOI 10.1016/j.hpb.2022.05.003↗
  10. The Fate of Resectable Pancreatic Adenocarcinoma After Neoadjuvant Chemotherapy. Co-author DOI 10.1097/mpa.0000000000001972↗
  11. An Immunocompetent Model of Pancreatic Cancer Resection and Recurrence. Last author DOI 10.1007/s11605-020-04681-9↗
  12. Neoadjuvant therapy alters the biliary microbiome in PDAC. First author DOI 10.1016/j.amjsurg.2020.12.050↗
  13. The war against pancreatic cancer in 2020 - advances on all fronts. First author DOI 10.1038/s41575-020-00410-4↗
  14. Hsp70 modulates immune response in pancreatic cancer through dendritic cells. Last author DOI 10.1080/2162402x.2021.1976952↗
  15. Modulation of Early Neutrophil Granulation: The Circulating Tumor Cell-Extravesicular Connection in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13112727↗
  16. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma: An Update on Heterogeneity and Therapeutic Targeting. Last author DOI 10.3390/ijms222413408↗
  17. Symphony in chaos: Immune orchestra during pancreatic cancer progression. Last author DOI 10.1016/j.ebiom.2020.102787↗
  18. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. Co-author DOI 10.1172/jci127515↗
  19. Targeting tumor intrinsic metabolic node in pancreatic cancer causes tumor regression,remodels extracellular matrix and sensitizes to anti-PD1 therapy Co-author DOI 10.1016/j.pan.2019.05.430↗
  20. ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining "stemness". Co-author DOI 10.1038/s41419-019-1408-5↗
  21. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy. Last author DOI 10.1053/j.gastro.2018.12.045↗
  22. Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival? Co-author DOI 10.1097/mpa.0000000000001339↗
  23. Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pa… Co-author DOI 10.1097/sla.0000000000003468↗
  24. Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials? First author DOI 10.1245/s10434-019-07787-w↗
  25. O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability. Co-author DOI 10.7150/thno.32615↗
  26. GRP78-mediated antioxidant response and ABC transporter activity confers chemoresistance to pancreatic cancer cells. Co-author DOI 10.1002/1878-0261.12322↗
  27. Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity. Co-author DOI 10.1016/j.canlet.2018.09.028↗
  28. Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression. Co-author DOI 10.1158/0008-5472.can-17-2320↗
  29. Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.11.026↗
  30. Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer. Co-author DOI 10.1038/s41598-017-01696-2↗
  31. Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer. Co-author DOI 10.1038/s41598-017-08447-3↗
  32. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Last author DOI 10.1007/s11605-015-2985-y↗
  33. Minnelide Overcomes Oxaliplatin Resistance by Downregulating the DNA Repair Pathway in Pancreatic Cancer. Co-author DOI 10.1007/s11605-015-3000-3↗
  34. Inhibition of NF-kappa B pathway leads to deregulation of epithelial-mesenchymal transition and neural invasion in pancreatic cancer. Co-author DOI 10.1038/labinvest.2016.109↗
  35. Evolution of novel therapeutic options for pancreatic cancer. First author DOI 10.1097/mog.0000000000000298↗
  36. Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1155↗
  37. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0470-6↗
  38. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3228↗
  39. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Co-author DOI 10.1016/j.canlet.2014.03.016↗
  40. Triptolide activates unfolded protein response leading to chronic ER stress in pancreatic cancer cells. Co-author DOI 10.1152/ajpgi.00466.2013↗
  41. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Co-author DOI 10.1158/1078-0432.ccr-13-2947↗
  42. Relevance of animal models of pancreatic cancer and pancreatitis to human disease. First author DOI 10.1053/j.gastro.2013.01.070↗
  43. Triptolide-induced cell death in pancreatic cancer is mediated by O-GlcNAc modification of transcription factor Sp1. Co-author DOI 10.1074/jbc.m113.500983↗
  44. miR-204 mediated loss of Myeloid cell leukemia-1 results in pancreatic cancer cell death. Co-author DOI 10.1186/1476-4598-12-105↗
  45. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Co-author DOI 10.1126/scitranslmed.3004334↗
  46. MUC1c regulates cell survival in pancreatic cancer by preventing lysosomal permeabilization. Co-author DOI 10.1371/journal.pone.0043020↗
  47. Myricetin induces pancreatic cancer cell death via the induction of apoptosis and inhibition of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. Co-author DOI 10.1016/j.canlet.2011.05.002↗
  48. Molecular targeted approaches for treatment of pancreatic cancer. Co-author DOI 10.2174/138161211796957427↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashok Kumar Saluja · 31 shared papers, 2011–2022 · strength 2.20
  2. Sulagna Banerjee · 25 shared papers, 2012–2021 · strength 1.69
  3. Tejeshwar Jain · 8 shared papers, 2020–2023 · strength 1.57
  4. John Bart Rose · 7 shared papers, 2022–2025 · strength 1.44
  5. Sushanth Reddy · 6 shared papers, 2022–2025 · strength 1.27
  6. Selwyn Maurice Vickers · 16 shared papers, 2011–2023 · strength 1.21
  7. Bhuwan Giri · 13 shared papers, 2016–2022 · strength 1.18
  8. Vineet Kumar Gupta · 10 shared papers, 2017–2022 · strength 0.91
  9. Nikita Sharma · 10 shared papers, 2017–2022 · strength 0.91
  10. Utpreksha Vaish · 5 shared papers, 2021–2025 · strength 0.85
  11. Vrishketan Sethi · 6 shared papers, 2019–2022 · strength 0.78
  12. Ahmer Irfan · 4 shared papers, 2022–2024 · strength 0.78
  13. Patricia Dauer · 8 shared papers, 2016–2019 · strength 0.63
  14. Alice Nomura · 9 shared papers, 2014–2018 · strength 0.58
  15. Anthony R. Ferrantella · 5 shared papers, 2019–2021 · strength 0.57
  16. Michelle M. Holland · 2 shared papers, 2025 · strength 0.54
  17. Annabelle L. Fonseca · 2 shared papers, 2025 · strength 0.54
  18. Chandler A. Annesi · 2 shared papers, 2025 · strength 0.54
  19. Martin J. Heslin · 2 shared papers, 2025 · strength 0.54
  20. Prateek Sharma · 4 shared papers, 2020–2022 · strength 0.51
  21. Olumide B. Gbolahan · 3 shared papers, 2022–2023 · strength 0.50
  22. Shrey Modi · 5 shared papers, 2016–2022 · strength 0.45
  23. Kousik Kesh · 5 shared papers, 2018–2020 · strength 0.43
  24. Nipun B. Merchant · 4 shared papers, 2019–2022 · strength 0.42
  25. Sundaram Ramakrishnan · 4 shared papers, 2016–2021 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.